| Authors: |
Shore N; Carolina Urologic Research Center, Myrtle Beach, SC., Nielsen SM; Labcorp Genetics Inc (formerly Invitae Corp), San Francisco, CA., Esplin ED; Labcorp Genetics Inc (formerly Invitae Corp), San Francisco, CA., Antonarakis ES; University of Minnesota, Masonic Cancer Center, Minneapolis, MN., Barata PC; Case Western Reserve University, Cleveland, OH., Beer TM; The Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Exact Sciences Corporation, Madison, WI., Beltran H; Dana Faber Cancer Institute, Boston, MA., Bryce A; City of Hope Cancer Center, Goodyear, AZ., Cookson MS; Stephenson Cancer Center, OU Health, The University of Oklahoma, Oklahoma City, OK., Crawford ED; University California, San Diego, La Jolla, CA., Dorff TB; City of Hope Cancer Center, Goodyear, AZ., George DJ; Duke Cancer Institute, Duke University, Durham, NC., Heath EI; Karmanos Cancer Institute, Detroit, MI., Helfand BT; NorthShore University HealthSystem/Endeavor Health, Evanston, IL., Hussain M; Northwestern Feinberg School of Medicine, Chicago, IL., Mckay RR; University California, San Diego, La Jolla, CA., Morgans AK; Dana Faber Cancer Institute, Boston, MA., Morris MJ; Memorial Sloan Kettering Cancer Center, New York, NY., Paller CJ; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD., Ross AE; Northwestern Feinberg School of Medicine, Chicago, IL., Sartor O; Mayo Clinic, Rochester, MN., Shen J; UCLA David Geffen School of Medicine, Los Angeles, CA., Sieber P; Keystone Urology Specialists, Lancaster, PA., Smith MR; Massachusetts General Hospital, Boston, MA., Wise DR; Perlmutter Cancer Center, NYU Langone Health, New York, NY., Armstrong AJ; Duke Cancer Institute, Duke University, Durham, NC. |
